Inspire Medical Systems, Inc. (INSP)
USD 186.97
(-1.96%)
USD 186.97
(-1.96%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 528.22 Million USD | 54.57% |
| 2022 | 341.74 Million USD | 70.77% |
| 2021 | 200.11 Million USD | 104.7% |
| 2020 | 97.75 Million USD | 42.91% |
| 2019 | 68.4 Million USD | 68.75% |
| 2018 | 40.53 Million USD | 79.77% |
| 2017 | 22.54 Million USD | 80.08% |
| 2016 | 12.52 Million USD | 140.67% |
| 2015 | 5.2 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 139.25 Million USD | -15.32% |
| 2024 Q2 | 166.04 Million USD | 19.24% |
| 2024 Q3 | 170.79 Million USD | 2.86% |
| 2023 FY | 528.22 Million USD | 54.57% |
| 2023 Q3 | 128.92 Million USD | 1.64% |
| 2023 Q2 | 126.84 Million USD | 17.43% |
| 2023 Q1 | 108 Million USD | -6.69% |
| 2023 Q4 | 164.45 Million USD | 27.56% |
| 2022 Q4 | 115.74 Million USD | 29.47% |
| 2022 Q2 | 77.21 Million USD | 30.04% |
| 2022 Q1 | 59.37 Million USD | -11.7% |
| 2022 FY | 341.74 Million USD | 70.77% |
| 2022 Q3 | 89.4 Million USD | 15.79% |
| 2021 Q3 | 53.06 Million USD | 16.77% |
| 2021 FY | 200.11 Million USD | 104.7% |
| 2021 Q1 | 34.37 Million USD | -11.52% |
| 2021 Q2 | 45.44 Million USD | 32.21% |
| 2021 Q4 | 67.24 Million USD | 26.73% |
| 2020 FY | 97.75 Million USD | 42.91% |
| 2020 Q1 | 18.05 Million USD | -20.37% |
| 2020 Q2 | 10.22 Million USD | -43.33% |
| 2020 Q3 | 30.63 Million USD | 199.45% |
| 2020 Q4 | 38.84 Million USD | 26.83% |
| 2019 Q3 | 17.4 Million USD | 16.52% |
| 2019 FY | 68.4 Million USD | 68.75% |
| 2019 Q1 | 13.39 Million USD | 0.22% |
| 2019 Q4 | 22.66 Million USD | 30.23% |
| 2019 Q2 | 14.93 Million USD | 11.51% |
| 2018 Q1 | 7.74 Million USD | -4.06% |
| 2018 Q2 | 8.83 Million USD | 14.04% |
| 2018 Q3 | 10.58 Million USD | 19.82% |
| 2018 Q4 | 13.36 Million USD | 26.25% |
| 2018 FY | 40.53 Million USD | 79.77% |
| 2017 Q1 | 4.1 Million USD | 0.0% |
| 2017 FY | 22.54 Million USD | 80.08% |
| 2017 Q2 | 4.66 Million USD | 13.78% |
| 2017 Q3 | 5.7 Million USD | 22.29% |
| 2017 Q4 | 8.07 Million USD | 41.54% |
| 2016 FY | 12.52 Million USD | 140.67% |
| 2015 FY | 5.2 Million USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Abbott Laboratories | 22.13 Billion USD | 97.614% |
| Allurion Technologies Inc. | 41.49 Million USD | -1172.919% |
| Artivion, Inc. | 229.17 Million USD | -130.488% |
| Avanos Medical, Inc. | 379.7 Million USD | -39.116% |
| Butterfly Network, Inc. | 16.85 Million USD | -3033.739% |
| Butterfly Network, Inc. | 16.85 Million USD | -3033.739% |
| Bio-Rad Laboratories, Inc. | 1.43 Billion USD | 63.096% |
| Boston Scientific Corporation | 9.89 Billion USD | 94.662% |
| Perspective Therapeutics, Inc. | 1.63 Million USD | -32226.989% |
| CONMED Corporation | 643.06 Million USD | 17.859% |
| Edwards Lifesciences Corporation | 4.62 Billion USD | 88.579% |
| Paragon 28, Inc. | 172.79 Million USD | -205.701% |
| Glaukos Corporation | 239.13 Million USD | -120.888% |
| Globus Medical, Inc. | 1.02 Billion USD | 48.229% |
| Integer Holdings Corporation | 418.28 Million USD | -26.282% |
| Medtronic plc | 19.45 Billion USD | 97.285% |
| Nevro Corp. | 290.06 Million USD | -82.108% |
| Owlet, Inc. | 22.58 Million USD | -2238.615% |
| Penumbra, Inc. | 682.64 Million USD | 22.621% |
| Vicarious Surgical Inc. | -1.85 Million USD | 28590.992% |
| Smith & Nephew plc | 3.7 Billion USD | 85.728% |
| Sonendo, Inc. | 10.72 Million USD | -4826.534% |
| STERIS plc | 2.23 Billion USD | 76.355% |
| Stryker Corporation | 13.05 Billion USD | 95.955% |
| Vapotherm, Inc. | 28.28 Million USD | -1767.634% |
| Zimmer Biomet Holdings, Inc. | 5.31 Billion USD | 90.053% |